The phase III CheckMate -649 demonstrated that first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in the overall survival and progression-free survival of patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma compared to treatment with chemotherapy alone.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
